Study the Assessment of Drug Value of National Price Negotiation from the Perspective of Societal Value
- VernacularTitle:基于社会价值视角的我国医保谈判药品价值评价探索
- Author:
Yi CHEN
1
;
Mengting WENG
1
Author Information
1. 清华大学医院管理研究院 广东 深圳 518055
- Publication Type:Journal Article
- Keywords:
price negotiation;
societal value;
drug value assessment;
value-based pricing;
Health Technology Assessment
- From:
Chinese Health Economics
2025;44(10):63-68
- CountryChina
- Language:Chinese
-
Abstract:
Objective:It aims to improve the accessment indexes of medical insurance drug value in China,it introduces a societal value dimension by combining international frontier research with China's medical insurance practices,and explores methods to improve the evaluation of drug accessment for medical insurance negotiations in China.Method:Based on Multi-Criteria Decision Analysis(MCDA),it uses literature review and related international guidelines to establishing a pool of social value evaluation indicators for medicines negotiated under China's medical insurance system.Based on the results of expert interviews(qualitative analysis)and Delphi method questionnaire surveys(quantitative analysis),indicators were selected,and the Analytic Hierarchy Process was used to calculate indicator weights,clarify indicator connotations,and establish scoring criteria.Result:A set of societal value framework are developed,composing 5 core indicators,13 secondary indicators and 4 innovative tertiary indicators.Conclusion:drug value assessment of national insurance is proposed to introduce societal value such as unmet needs,disease severity,and public health impact.It is proposed to calculate the comprehensive societal value score for the drug based on MCDA,adjust the pathway for the threshold of Quality-adjusted Life-year,so as to conduct further discuss.
